Ypsomed
Ypsomed Holding AG, commonly known as Ypsomed, is a leading Swiss company headquartered in Burgdorf, Switzerland (CH). Founded in 1984, Ypsomed has established itself as a key player in the medical technology industry, specialising in the development and manufacturing of innovative drug delivery systems and diabetes management solutions. With a strong presence in Europe and expanding operations in Asia and North America, Ypsomed is renowned for its cutting-edge products, including insulin delivery devices and pen systems. The company’s commitment to quality and user-centric design sets it apart in a competitive market. Ypsomed has achieved significant milestones, including partnerships with major pharmaceutical companies, solidifying its position as a trusted provider in the healthcare sector.
DitchCarbon Score
How does Ypsomed's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Ypsomed's score of 59 is higher than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Ypsomed's reported carbon emissions
In 2023, Ypsomed AG reported a total of approximately 2,404,000 kg CO2e in Scope 1 emissions, with no reported Scope 2 emissions. The company has made significant commitments to reduce its carbon footprint, aiming for net-zero greenhouse gas emissions across its entire value chain by 2040, using 2020 as the base year. Ypsomed has set near-term targets to reduce absolute Scope 1 and 2 emissions by 32% by 2027 and aims for a long-term reduction of 90% by 2030. Additionally, the company plans to cut Scope 3 emissions by 52% per million CHF of value added by 2030 and by 97% per million CHF by 2040. In 2022, Ypsomed's total emissions were approximately 87,423,000 kg CO2e, with Scope 1 emissions at about 2,557,000 kg CO2e and Scope 3 emissions making up the majority at approximately 84,867,000 kg CO2e. The company has demonstrated a commitment to sustainability within the healthcare sector, aligning its targets with industry standards to mitigate climate change impacts.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|
| Scope 1 | - | - | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | - | - | 00,000 | - | 0,000 | - |
| Scope 3 | - | 000,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Ypsomed is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
